MedPath

Di Perri Giovanni

🇧🇪Belgium
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:1

Trial Phases

1 Phases

Phase 4:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 4
2 (100.0%)

Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)

Phase 4
Terminated
Conditions
Hiv
Neurocognitive Dysfunction
Interventions
First Posted Date
2017-05-23
Last Posted Date
2020-11-06
Lead Sponsor
Giovanni Di Perri
Target Recruit Count
38
Registration Number
NCT03163277
Locations
🇮🇹

University of Torino, Torino, Italy

Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir

Phase 4
Terminated
Conditions
HIV Infection
Osteopenia
Interventions
Drug: tenofovir/emtricitabine and atazanavir and ritonavir
First Posted Date
2013-07-18
Last Posted Date
2018-10-17
Lead Sponsor
Giovanni Di Perri
Target Recruit Count
4
Registration Number
NCT01902186
Locations
🇮🇹

University of Milano, Milano, Italy

🇮🇹

University of Torino, Torino, Italy

Early- and Late-onset Candidemia

Completed
Conditions
Candidemia
First Posted Date
2011-07-29
Last Posted Date
2014-12-04
Lead Sponsor
Giovanni Di Perri
Target Recruit Count
400
Registration Number
NCT01406093
Locations
🇮🇹

Hospital San Giovanni Battista - Molinette, Torino, Italy

News

No news found
© Copyright 2025. All Rights Reserved by MedPath